FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100021456> ?p ?o ?g. }

• W2100021456 endingPage "5" @default.
• W2100021456 startingPage "1" @default.
• W2100021456 abstract "The incidence of diabetes and its complications is increasing to staggering proportions. Presently the WHO estimates an overall prevalence of 130 million, but by 2025 there will be 300 million individuals with diabetes mellitus. The incidence of diabetic neuropathy approaches 50% in most diabetic populations; there is no treatment, and its consequences in the form of foot ulceration and amputation are financially punishing for health care providers. Attempts to develop treatments have faltered for want of an understanding of the aetiology of diabetic neuropathy. As a consequence, 1999 saw the demise of two further compounds: recombinant growth factor by Roche-Genentech and the aldose reductase inhibitor zopolrestat, by Pfizer, both had reached phase III clinical trials. They joined an impressive list of at least 30 other compounds which have reached phase III clinical trials and failed to establish efficacy. The need to establish a viable treatment for human diabetic neuropathy is absolutely paramount. To provide a rational answer as to whether angiotensin-converting enzyme (ACE) inhibitors can prevent human diabetic neuropathy, two major issues need addressing: 1) Does vascular dysfunction cause human diabetic neuropathy? 2) Can ACE inhibitors ameliorate diabetic vascular dysfunction and hence neuropathy? Epidemiological studies support a strong association between neuropathy, retinopathy and nephropathy. Microangiopathy is deemed as the root cause of both nephropathy, and retinopathy and mounting evidence provides support for a vascular basis of diabetic neuropathy. ACE inhibitors appear to correct many of the abnormalities associated with the vascular dysfunction found in diabetes. Thus effective ACE inhibition impacts very positively on cardiovascular outcomes in patients with ischaemic heart disease, particularly in diabetic patients. ACE inhibition also prevents the development and progression of incipient and established diabetic nephropathy and delays progression of background retinopathy. Quinapril improves measures of diabetic autonomic neuropathy. Our recent study has demonstrated a significant improvement in peripheral neuropathy following 12 months of treatment with the ACE inhibitor trandolapril." @default.
• W2100021456 created "2016-06-24" @default.
• W2100021456 creator A5026945028 @default.
• W2100021456 date "2000-01-01" @default.
• W2100021456 modified "2023-10-16" @default.
• W2100021456 title "Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?" @default.
• W2100021456 cites W1968264094 @default.
• W2100021456 cites W1971421020 @default.
• W2100021456 cites W1972009778 @default.
• W2100021456 cites W1975831146 @default.
• W2100021456 cites W1975879524 @default.
• W2100021456 cites W1985709687 @default.
• W2100021456 cites W1986081485 @default.
• W2100021456 cites W1987124008 @default.
• W2100021456 cites W1988144115 @default.
• W2100021456 cites W1994276936 @default.
• W2100021456 cites W2000959775 @default.
• W2100021456 cites W2001568955 @default.
• W2100021456 cites W2002728967 @default.
• W2100021456 cites W2004447381 @default.
• W2100021456 cites W2009948798 @default.
• W2100021456 cites W2022268466 @default.
• W2100021456 cites W2043490453 @default.
• W2100021456 cites W2047202595 @default.
• W2100021456 cites W2051178050 @default.
• W2100021456 cites W2052207873 @default.
• W2100021456 cites W2052382954 @default.
• W2100021456 cites W2052939510 @default.
• W2100021456 cites W2058264335 @default.
• W2100021456 cites W2059722075 @default.
• W2100021456 cites W2060830788 @default.
• W2100021456 cites W2060977296 @default.
• W2100021456 cites W2062472483 @default.
• W2100021456 cites W2062701334 @default.
• W2100021456 cites W2064464513 @default.
• W2100021456 cites W2068013747 @default.
• W2100021456 cites W2073749763 @default.
• W2100021456 cites W2074328785 @default.
• W2100021456 cites W2075503919 @default.
• W2100021456 cites W2083698504 @default.
• W2100021456 cites W2093133405 @default.
• W2100021456 cites W2094098736 @default.
• W2100021456 cites W2097846625 @default.
• W2100021456 cites W2110114424 @default.
• W2100021456 cites W2113105285 @default.
• W2100021456 cites W2122357131 @default.
• W2100021456 cites W2142057145 @default.
• W2100021456 cites W2149471545 @default.
• W2100021456 cites W2153372656 @default.
• W2100021456 cites W2155217360 @default.
• W2100021456 cites W2164694321 @default.
• W2100021456 cites W2302392835 @default.
• W2100021456 cites W2312400976 @default.
• W2100021456 cites W2337454357 @default.
• W2100021456 cites W4210985378 @default.
• W2100021456 cites W4245107010 @default.
• W2100021456 doi "https://doi.org/10.3109/07853890008995903" @default.
• W2100021456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10711571" @default.
• W2100021456 hasPublicationYear "2000" @default.
• W2100021456 type Work @default.
• W2100021456 sameAs 2100021456 @default.
• W2100021456 citedByCount "46" @default.
• W2100021456 countsByYear W21000214562012 @default.
• W2100021456 countsByYear W21000214562014 @default.
• W2100021456 countsByYear W21000214562015 @default.
• W2100021456 countsByYear W21000214562016 @default.
• W2100021456 countsByYear W21000214562017 @default.
• W2100021456 countsByYear W21000214562019 @default.
• W2100021456 countsByYear W21000214562020 @default.
• W2100021456 countsByYear W21000214562021 @default.
• W2100021456 countsByYear W21000214562022 @default.
• W2100021456 countsByYear W21000214562023 @default.
• W2100021456 crossrefType "journal-article" @default.
• W2100021456 hasAuthorship W2100021456A5026945028 @default.
• W2100021456 hasConcept C126322002 @default.
• W2100021456 hasConcept C134018914 @default.
• W2100021456 hasConcept C141071460 @default.
• W2100021456 hasConcept C177713679 @default.
• W2100021456 hasConcept C27016395 @default.
• W2100021456 hasConcept C2776204877 @default.
• W2100021456 hasConcept C2776513394 @default.
• W2100021456 hasConcept C2778313320 @default.
• W2100021456 hasConcept C2779178840 @default.
• W2100021456 hasConcept C2779829184 @default.
• W2100021456 hasConcept C2779922275 @default.
• W2100021456 hasConcept C2781184683 @default.
• W2100021456 hasConcept C555293320 @default.
• W2100021456 hasConcept C71924100 @default.
• W2100021456 hasConcept C84393581 @default.
• W2100021456 hasConceptScore W2100021456C126322002 @default.
• W2100021456 hasConceptScore W2100021456C134018914 @default.
• W2100021456 hasConceptScore W2100021456C141071460 @default.
• W2100021456 hasConceptScore W2100021456C177713679 @default.
• W2100021456 hasConceptScore W2100021456C27016395 @default.
• W2100021456 hasConceptScore W2100021456C2776204877 @default.
• W2100021456 hasConceptScore W2100021456C2776513394 @default.
• W2100021456 hasConceptScore W2100021456C2778313320 @default.
• W2100021456 hasConceptScore W2100021456C2779178840 @default.

• next